Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1983 - Afatinib (AFA) plus Bevacizumab (BEV) Combination after Osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): a multicenter prospective single arm phase II study (ABCD-study)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Immunotherapy

Tumour Site

Presenters

Akito Hata

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

A. Hata1, N. Katakami2, K. Nishino3, M. Mori4, T. Yokoyama5, T. Kurata6, M. Tachihara7, N. Takase8, H. Daga9, T. Kijima10, S. Morita11, K. Sakai12, K. Nishio13, M. Satouchi14, S. Negoro8

Author affiliations

  • 1 Department Of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, 650-0046 - Kobe/JP
  • 2 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 3 Department Of Thoracic Oncology, Osaka International Cancer Institute, Osaka/JP
  • 4 Department Of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka/JP
  • 5 Department Of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki/JP
  • 6 Department Of Respiratory Medicine, First Department of Internal Medicine, Kansai Medical University, Hirakata/JP
  • 7 Department Of Respiratory Medicine, Kobe University Hospital, Kobe/JP
  • 8 Cancer Center, Takarazuka City Hospital, Takarazuka/JP
  • 9 Department Of Medical Oncology, Osaka City General Hospital, 534-0021 - Osaka/JP
  • 10 Respiratory Medicine, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP
  • 11 Biomedical Statistics And Bioinformatics, Kyoto University Graduate School of Medicine 54 Kawahara-cho,Shogoin,Sakyo-ku, Kyoto/JP
  • 12 Department Of Genome Biology, Kindai University Faculty of Medicine, Osaka-sayama/JP
  • 13 Department Of Genome Biology, Kindai University Faculty of Medicine, 589-8511 - Osaka/JP
  • 14 Department Of Thoracic Oncology, Hyogo Cancer Center, Hyogo/JP
More

Resources

Abstract 1983

Background

3rd-generation EGFR-TKI, OSIME showed a remarkable efficacy for T790M+ NSCLC. Moreover, OSIME has proven superior progression-free survival (PFS) over 1st-generation EGFR-TKIs in front-line setting, and it will be widely used in front-line and later settings. Various resistant mechanisms were reported: C797S (cis/trans); EGFR uncommon mutations such as E709K and L844V; T790M- conversion; HER2-amp; MET-amp; PIK3CA/BRAF mutations; and histological transformation such as small cell and EMT. AFA is an irreversible EGFR-TKI with a potency as pan-HER inhibitor. Preclinical and clinical studies showed high sensitivity to EGFR uncommon mutations. Preclinical studies also showed a synergistic effect of AFA and BEV after acquired resistance (AR) to EGFR-TKIs. Our previously-conducted phase II study found a promising efficacy of AFA+BEV after AR: response rate (RR), 18.8%; disease control rate (DCR), 90.7%; and median PFS (mPFS), 6.3 months. Notably, preclinical data has suggested EGFR-TKI+BEV combination could overcome MET-associated resistance. Based on the above background, we hypothesize several resistant mechanisms (e.g., C797S (trans), uncommon EGFR mutations, and HER2) to OSIME are sensitive to AFA, and synergism of additional BEV maximizes AFA sensitivity.

Trial design

This ABCD-study is a phase II study conducted by HANSHIN Oncology Group. ECOG PS 0-1 patients with EGFR-mutant NSCLC are enrolled after failure of OSIME. Liquid/histological rebiopsies before enrollment after OSIME failure are essential to examine the resistant mechanisms. Liquid /histological samples are analyzed to confirm gene mutations/fusions and copy-number gain using next-generation sequencers. AFA is prescribed at 30-40 mg QD, and BEV is administered at 15 mg/kg tri-weekly until progression. The primary endpoint is PFS. Sample size of 26 is based on a null mPFS of 4.0 months, an alternative mPFS of 6.0 months, power of 80% and one-sided 15% of type I error. We plan an exploratory analysis regarding differential efficacies according to each resistant mechanism.

Clinical trial identification

UMIN000030545.

Legal entity responsible for the study

The authors.

Funding

Boehringer Ingelheim.

Editorial Acknowledgement

We thank Mr. David Martin for English editing.

Disclosure

A. Hata: Lecture fee: Boehringer Ingelheim; Financially support analysis of liquid/histological samples: Boehringer Ingelheim. N. Katakami: Honoraria and Research fund: Boehringer Ingelheim. K. Nishino, T. Kurata, M. Tachihara, H. Daga, T. Kijima, S. Morita, K. Nishio, M. Satouchi: Honoraria: Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.